Therefore, both IGF1-R inhibitors could enhance the pro-apoptotic and antiproliferative impacts of regorafenib and VK1 in hepatocellular carcinoma downregulating both MAPK and PI3K/AKT signaling pathways (Refolo et al., 2017). This evidence concerns the gene PIK3CD and hepatocellular carcinoma.